Article
KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study.
Cells - 15 Jan 2020
Garcia-Carbonero Nuria, Martinez-Useros Javier, Li Weiyao, Orta Alberto, Perez Nuria, Carames Cristina, Hernandez Tatiana, Moreno Irene, Serrano Gloria, Garcia-Foncillas Jesus
Abstract excerpt
KRAS mutation is a confirmed predictive biomarker for anti-EGFR monoclonal antibody therapy response for metastatic colorectal cancer. However, its prognosis impact and the predictive potential for first-line standard chemotherapy remains unclear. On the other hand, V600E mutation is the most frequent and studied mutation in the BRAF gene, and it has been associated with a poor outcome of patients and a low...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.